Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Stevenson, F. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stevenson, F. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 10:1413-1418, 1999
© 1999 European Society for Medical Oncology

review-article

DNA vaccines against cancer: From genes to therapy

F. K. Stevenson

Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals Trust Southampton, UK

Correspondence to: Professor Freda K. Stevenson, Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals Trust, Southampton SO16 6YD, UK. E-mail: fs{at}soton.ac.uk

After an erratic history, there is at last a clear opportunity for mobilizing an immune attack against cancer cells. The new strategies are dependent on the techniques of molecular biology, which are able both to identify potential target tumor antigens at the gene level, and to help to unravel the complexities of immune mechanisms required. Vaccine delivery systems can also be genetic, with DNA vaccines able to act as viral mimics and enter several antigen processing pathways. Rational vaccine designs can be rapidly tested in models and selected for pilot clinical trials. One difficulty faced by tumor antigens is that they may be weak, and therefore fail to engage the immune system. Attaching genes encoding alert signals appears to solve this problem. We have focused initially on idiotypic determinants of B-cell tumors, where the encoding variable region genes can induce protective anti-idiotypic immunity if delivered as a fusion protein with a fragment of Tetanus toxin. This model may have relevance for alternative tumor antigens. A clinical trial of patients with lymphoma is in progress, and wider application may be limited only by the ability to bring patients into clinical remission prior to vaccination.

B-cell lymphoma, DNA vaccines, myeloma, tumor antigens, variable region genes


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
M. C. Wolkers, M. Toebes, M. Okabe, J. B. A. G. Haanen, and T. N. M. Schumacher
Optimizing the Efficacy of Epitope-Directed DNA Vaccination
J. Immunol., May 15, 2002; 168(10): 4998 - 5004.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. M. Vose, B. C.-H. Chiu, B. D. Cheson, J. Dancey, and J. Wright
Update on Epidemiology and Therapeutics for Non-Hodgkin's Lymphoma
Hematology, January 1, 2002; 2002(1): 241 - 262.
[Abstract] [Full Text]

Home page
 J. Leukoc. Biol.Home page
D. J. Shedlock and D. B. Weiner
DNA vaccination: antigen presentation and the induction of immunity
J. Leukoc. Biol., December 1, 2000; 68(6): 793 - 806.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.